ORCA
Online Research @ Cardiff
Browse by Current Cardiff authors
 | Up a level |
Number of items: 15.
| Hulin-Curtis, Sarah, Davies, James A., Jones, Rachel, Hudson, Emma, Hanna, Louise, Chester, John D. and Parker, Alan L. 2018. Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus. Oncotarget 9 (41) , pp. 26328-26341. 10.18632/oncotarget.25242 |
|
|
| Hulin-Curtis, Sarah, Williams, Helen, Wadey, Kerry S., Sala-Newby, Graciela B. and George, Sarah J. 2017. Targeting Wnt/b-catenin activated cells with dominant-negative N-cadherin to reduce neointima formation. Molecular Therapy - Methods & Clinical Development 5 , pp. 191-199. 10.1016/j.omtm.2017.04.009 |
|
|
| Hulin-Curtis, Sarah, Uusi-Kerttula, Hanni, Jones, R., Hanna, L., Chester, John D. and Parker, Alan L. 2016. Evaluation of CD46 re-targeted adenoviral vectors for clinical ovarian cancer intraperitoneal therapy. Cancer Gene Therapy 23 (7) , pp. 229-234. 10.1038/cgt.2016.22 |
|
|
| Williams, Helen, Mill, Carina A. E., Monk, Bethan A., Hulin-Curtis, Sarah, Johnson, Jason and George, Sarah J. 2016. Wnt2 and WISP-1/CCN4 induce intimal thickening via promotion of smooth muscle cell migration. Arteriosclerosis Thrombosis and Vascular Biology 36 (7) , pp. 1417-1424. 10.1161/ATVBAHA.116.307626 |
|
|
| Uusi-Kerttula, Hanni, Davies, James, Curtis, Sarah, Chester, John and Parker, Alan 2016. Pseudotyped αvβ6 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget 7 (19) , pp. 27926-27937. 10.18632/oncotarget.8545 |
|
|
Uusi-Kerttula, Hanni, Hulin-Curtis, Sarah, Davies, James Anthony and Parker, Alan L.
2015.
Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications.
Viruses
7
(11)
, pp. 6009-6042.
10.3390/v7112923
|
|
| Hulin-Curtis, Sarah, Uusi-Kerttula, Hanni, Jones, Rachel, Baker, Andrew, Chester, John D. and Parker, Alan L. 2015. Evaluation of CD46 utilising adenoviral vectors for clinical ovarian cancer applications [Abstract]. Human Gene Therapy 26 (9) , A33-A34. 10.1089/hum.2015.29005.abstracts |
|
| Galea, Gabriel L., Meakin, Lee B., Williams, Christopher M., Hulin-Curtis, Sarah, Lanyon, Lance E., Poole, Alastair W. and Price, Joanna S. 2014. Protein kinase Cα (PKCα) regulates bone architecture and osteoblast activity. Journal of Biological Chemistry 289 (37) , pp. 25509-25522. 10.1074/jbc.M114.580365 |
|
|
| Tully, L. J., Murphy, A. M., Smith, R. K. W., Hulin-Curtis, Sarah, Verheyen, K. L. P. and Price, J. S. 2014. Polymorphisms inTNCandCOL5A1genes are associated with risk of superficial digital flexor tendinopathy in National Hunt thoroughbred racehorses. Equine Veterinary Journal 46 (3) , pp. 289-293. 10.1111/evj.12134 |
|
|
| Williams, H., Mill, C. A., Hulin-Curtis, Sarah, Johnson, J. L. and George, S. J. 2014. Wnt inducible soluble protein 1 (WISP-1) promotes VSMC migration and intimal thickening. Atherosclerosis 232 (2) , e2. 10.1016/j.atherosclerosis.2013.11.004 |
|
|
| Hulin-Curtis, Sarah, Sharif, M., Bidwell, J. L. and Perry, M. J. 2013. Evaluation of NFKB1A variants in patients with knee osteoarthritis. International Journal of Immunogenetics 40 (4) , pp. 272-279. 10.1111/iji.12020 |
|
|
| Hulin-Curtis, Sarah, Bidwell, J. L. and Perry, M. J. 2013. Association between CCL2 haplotypes and knee osteoarthritis. International Journal of Immunogenetics 40 (4) , pp. 280-283. 10.1111/iji.12015 |
|
|
| Hulin-Curtis, Sarah 2012. Evaluation of IL18 and IL18R1 polymorphisms: genetic susceptibility to knee osteoarthritis. International Journal of Immunogenetics 39 (2) , pp. 106-109. 10.1111/j.1744-313X.2011.01060.x |
|
|
| Hulin-Curtis, Sarah, Bidwell, J. L. and Perry, M. J. 2012. Tumour necrosis factor receptor superfamily member 11B polymorphisms and association with knee osteoarthritis in women. International Journal of Immunogenetics 39 (3) , pp. 207-209. 10.1111/j.1744-313X.2012.01083.x |
|
|
| Hulin-Curtis, Sarah, Petit, Dominique, Figg, W. Douglas, Hsing, Ann W. and Reichardt, Juergen K.V. 2010. Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future Oncology 6 (12) , pp. 1897-1913. 10.2217/fon.10.149 |
|
|
Cardiff University Information Services